Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
12.40
-0.42 (-3.28%)
At close: Feb 4, 2026, 4:00 PM EST
12.10
-0.30 (-2.42%)
After-hours: Feb 4, 2026, 5:41 PM EST
Vor Biopharma Employees
Vor Biopharma had 154 employees as of September 30, 2025. The number of employees decreased by 5 or -3.14% compared to the same quarter last year.
Employees
154
Change
-5
Growth
-3.14%
Revenue / Employee
n/a
Profits / Employee
-$15,906,175
Market Cap
514.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| ADC Therapeutics | 265 |
| Prothena Corporation | 163 |
| Kyverna Therapeutics | 129 |
| Niagen Bioscience | 104 |
| Invivyd | 100 |
| Solid Biosciences | 100 |
| Verastem | 78 |
VOR News
- 4 weeks ago - Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors - GlobeNewsWire
- 7 weeks ago - Vor Bio Announces $150 Million Private Placement - GlobeNewsWire
- 2 months ago - Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial - Benzinga
- 3 months ago - Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - GlobeNewsWire
- 3 months ago - Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock - GlobeNewsWire
- 3 months ago - Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China - GlobeNewsWire